International Patent: SPARSENTAN FOR THE TREATMENT OF PATIENTS POST KIDNEY TRANSPLANTATION WITH PROTEINURIC IGA NEPHROPATHY OR FSGS

GENEVA, Aug. 7 -- TRAVERE THERAPEUTICS, INC. filed a patent application (US2026/013396) for “SPARSENTAN FOR THE TREATMENT OF PATIENTS POST KIDNEY TRANSPLANTATION WITH PROTEINURIC IGA NEPHROPATHY OR FSGS”. With publication no. WO/2026/165438, here are the other details related to the patent application:

Kind: Initial Publication with ISR [A1]

IPC: A61K 31/422

Notably, the patent application was submitted under the International Patent Classification (IPC) system, which is managed by the World Intellectual Property Organization (WIPO).

Disclaimer: Curated by HT Syndication....